AGEM400(HES), a novel erythropoietin mimetic peptide conjugated to hydroxyethyl starch with excellent In Vitro efficacy

Open Hematology Journal

Volumn 4, Issue 1, 2010, Pages 1-14

  Greindl, Alexandra ^a   Kessler, Claudia ^a   Breuer, Bettina ^a   Haberl, Udo ^a   Rybka, Andreas ^a   Emgenbroich, Marco ^a   Pötgens, Andy J G ^a   Frank, Hans Georg ^a  

^a AplaGen GmbH   (Germany)

Author keywords

Erythropoietin; Erythropoietin mimetic peptide (EMP); Erythropoietin receptor; Hydroxyethyl starch (HES)

Indexed keywords

ERYTHROPOIETIN ANTIBODY; ERYTHROPOIETIN MIMETIC PEPTIDE; ERYTHROPOIETIN RECEPTOR; HETASTARCH; MITOGEN ACTIVATED PROTEIN KINASE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PEPTIDOMIMETIC AGENT; RECOMBINANT ERYTHROPOIETIN; STAT5 PROTEIN; UNCLASSIFIED DRUG;

ANEMIA; ARTICLE; BINDING COMPETITION; BONE MARROW CELL; CELL LINE; CELL SURVIVAL; CLONOGENIC ASSAY; CONTROLLED STUDY; DRUG EFFICACY; DRUG INDICATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROPOIESIS; HUMAN; HUMAN CELL; IN VITRO STUDY; INHIBITION KINETICS; KIDNEY FAILURE; MALIGNANT NEOPLASTIC DISEASE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RECEPTOR BINDING;

EID: 78249278473     PISSN: None     EISSN: 18742769     Source Type: Journal    
DOI: 10.2174/1874276901004010001     Document Type: Article

References (40)

1. Macdougall IC. Recent advances in erythropoietic agents in renal anemia. Semin Nephrol 2006; 26: 313-8.
2. Macdougall IC, Ashenden M. Current and upcoming erythropoiesis-stimulating agents, iron products, and other novel anemia medications. Adv Chronic Kidney Dis 2009; 16: 117-30.
3. Elliot S, Pham E, Macdougall IC. Erythropoietins: a common mechanism of action. Exp Hematol 2008; 36: 1573-84.
4. Jelkmann W. Developments in the therapeutic use of erythropoiesis stimulating agents. Br J Haematol 2008; 141: 287-97.
5. Wrighton NC, Farrell FX, Chang R, et al. Small peptides as potent mimetics of the protein hormone erythropoietin. Science 1996; 273: 458-63.
6. Stead RB, Lambert J, Wessels D, et al. Evaluation of the safety and pharmacodynamics of Hematide, a novel erythropoietic agent, in a phase 1, double blind, placebo-controlled, dose escalation study in healthy volunteers. Blood 2006; 108: 1830-4.
7. Bouman-Thio E, Franson K, Miller B, et al. A phase I, single and fractionated, ascending-dose study evaluating the safety, pharmacokinetics, pharmacodynamics, and immunogenicity of an erythropoietin mimetic antibody fusion protein (CNTO 528) in healthy male subjects. J Clin Pharmacol 2008; 48: 1197-207.
8. Fan Q, Leuther KK, Holmes CP, et al. Preclinical evaluation of Hematide, a novel erythropoiesis stimulating agent, for the treatment of anemia. Exp Hematol 2006; 34: 1303-11.
9. Bugelski PJ, Capocasale RJ, Makropoulos D, et al. CNTO 530: Molecular pharmacology in human UT-7EPO cells and pharmacokinetics and pharmacodynamics in mice. J Biotechnol 2008; 134: 171-80.
10. Schellekens H. Immunological mechanisms of EPO-associated pure red cell aplasia. Best Pract Res Clin Haematol 2005; 18: 473-80.
11. Casadevall N. What is antibody-mediated pure red cell aplasia (PRCA)? Nephrol Dial Transplant 2005; 20, (suppl 4): iv3-8.
12. Elliot S, Egrie J, Browne J, et al. Control of rHuEPO biological activity: The role of carbohydrate. Exp Hematol 2004; 32: 1146-55.
13. Macdougall IC. CERA (continuous erythropoietin receptor activator): A new erythropoiesis-stimulating agent for the treatment of anemia. Curr Hematol Rep 2005; 4: 436-40.
14. Malik F, Delgado C, Knusli C, Irvine AE, Fisher D, Francis GE. Polyethylene glycol (PEG)-modified granulocyte-macrophage colony-stimulating factor (GM-CSF) with conserved biological activity. Exp Hematol 1992; 20: 1028-35.
15. Bailon P, Palleroni A, Schaffer CA, et al. Rational design of a potent, long lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C. Bioconjug Chem 2001; 12: 195-202.
16. Vicent MJ, Dieudonné L, Carbajo RJ, Pineda-Lucena A. Polymer conjugates as therapeutics: future trends, challenges and opportunities. Expert Opin Drug Deliv 2008; 5: 593-614.
17. Bailon P, Won CY. PEG-modified biopharmaceuticals. Expert Opin Drug Deliv 2009; 6: 1-16.
18. Webster R, Didier E, Harris P, et al. PEGylated proteins: evaluation of their safety in the absence of definitive metabolism studies. Drug Metab Dispos 2007; 35: 9-16.
19. Yamaoka T, Tabata Y, Ikada Y. Distribution and tissue uptake of poly(ethylene glycol) with different molecular weights after intravenous administration to mice. J Pharm Sci 1994; 83: 601-6.
20. Woodburn KW, Schatz PJ, Fong K, et al. Preclinical safety and pharmacology of Hematide, a peptidic erythropoiesis stimulating agent (ESA), in rats and monkeys. Drug Chem Toxicol 2008; 31: 229-44.
21. Woodburn KW, Wilson SD, Fong K, et al. Chronic preclinical safety evaluation of Hematide, a pegylated peptidic erythropoiesis stimulating agent in monkeys. Haematologica 2008; 93: 1376-9.
22. Boldt J. Modern rapidly degradable hydroxyethyl starches: current concepts. Anesth Analg 2009; 108: 1574-82.
23. Johnson DL, Farrell FX, Barbone FB, et al. Identification of a 13 amino acid peptide mimetic of erythropoietin and description of amino acids critical for the mimetic activity of EMP1. Biochemistry 1998; 37: 3699-710.
24. Johnson DL, Farrell FX, Barbone FB, et al. Amino-terminal dimerization of an erythropoietin mimetic peptide results in increased erythropoietic activity. Chem Biol 1997; 4: 939-50.
25. Knorr K, Emgenbroich M, Büngerner C. Process for forming disulphide bridges. WIPO patent WO/2008/077621. 2008 July.
26. Kitamura T, Tange T, Terasawa T, et al. Establishment and characterization of a unique human cell line that proliferates dependently on GM-CSF, IL-3, or erythropoietin. J Cell Physiol 1989; 140: 323-34.
27. Komatsu N, Nakauchi H, Miwa A, et al. Establishment and characterization of a human leukemic cell line with megakaryocytic features: Dependency on granulocyte-macrophage colony-stimulating factor, interleukin-3, or erythropoietin for growth and survival. Cancer Res 1991; 51: 341-8.
28. Komatsu N, Yamamoto M, Fujita H, et al. Establishment and characterization of an erythropoietin-dependent subline, UT-7/EPO, derived from human leukaemia cell line, UT-7. Blood 1993; 82: 456-64.
29. Hammerling U, Kroon R, Wilhelmsen T, Sjödin L. In vitro bioassay for human erythropoietin based on proliferative stimulation of an erythroid cell line and analysis of carbohydrate-dependent microheterogeneity. J Pharm Biomed Anal 1996; 14: 1455-69.
30. Wrighton NC, Balasubramanian P, Barbone FP, et al. Increased potency of an erythropoietin peptide mimetic through covalent dimerization. Nat Biotechnol 1997; 15: 1261-5.
31. Vadas O, Rose K. Multivalency - a way to enhance binding avidities and bioactivity - preliminary applications to EPO. J Peptide Sci 2007; 13: 581-7.
32. Lehmann GB, Asskali F, Boll M et al. HES 130/0.42 shows less alterations of pharmacokinetics than HES 200/0.5 when dosed repeatedly. Br J Anaesth 2007; 98: 635-44.
33. Eisenbach C, Schönfeld AH, Vogt N, et al. Pharmacokinetics and organ storage of hydroxyethyl starch in acute hemodilution in pigs: influence of molecular weight and degree of substitution. Intensive Care Med 2007; 33: 1637-44.
34. Leuschner J, Opitz J, Winkler A, Scharpf R, Bepperling F. Tissue storage of 14C-labelled hydroxyethyl starch (HES) 130/0.4 and HES 200/0.5 after repeated intravenous administration to rats. Drugs R D 2003; 4: 331-8.
35. Wiedermann CJ. Hydroxyethyl starch - can the safety problem be ignored? Wien Klin Wochenschr 2004; 116: 583-94.
36. Waitzinger J, Bepperling F, Pabst G, Opitz J, Müller M, Baron J. Pharmacokinetics and tolerability of a new hydroxyethylstarch (HES) specification [HES(130/0.4)] after single-dose infusion of 6% or 10% solutions in healthy volunteers. Clin Drug Invest 1998; 16: 151-60.
37. Jungheinrich C, Scharpf R, Wargenau M, Bepperling F, Baron JF. The pharmacokinetics and tolerability of an intravenous infusion of the new hydroxyethylstarch 130/0.4 (6%, 500ml) in moild-to-severe renal impairment. Anesth Analg 2002; 95: 544-51.
38. Waitzinger J, Bepperling F, Pabst G, Opitz J. Hydroxyethylstarch (HES) [130/0.4], a new HES specification: pharmacokinetics and safety after multiple infusions of 10% solution in healthy volunteers. Drugs R D 2003; 4: 149-57.
39. Duliege AM, Stead R, Leuther K, Woodburn KW, Naso RB. Erythropoietin rceptor peptide formulations and uses. WIPO patent WO/2009/025958. 2009 Feb.
40. Woodburn KW, Fan Q, Winslow S, et al. Hematide is immunologically distinct from erythropoietin and corrects anemia induced by antierythropoietin antibodies in a rat pure red cell aplasia model. Exp Hematol 2007; 35: 1201-8.